A similar molecule is sorafenib, interfering with VEGF-R2 and VEGF-R3, PDGF receptor β, and c-KIT receptor [174], and is FDA approved for advanced renal cell carcinoma [175]. This evidence concerns the gene FLT4 and hereditary clear cell renal cell carcinoma.